title: Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function?
abstract: Twenty-seven patients (15 diabetics and 12 non-diabetics) with normal to moderately reduced renal function underwent femoral angiography with a low-osmolar contrast agent, iohexol (Omnipaque), under perexaminatory hydration. Fourteen patients were randomised to pretreatment with oral felodipine extended release (Plendil) 10 mg and 13 patients to placebo 3-4 h before angiography. GFR measured with [51Cr] EDTA-clearance decreased 24 hours after the angiography in the felodipine group from GFR 52.5 +/- 18.6 (mean +/- SD) to 46.2 +/- 16.5 ml/min (p < 0.01) and in the placebo group from 70.6 +/- 18.6 to 62.6 +/- 26.4 ml/min (p < 0.01). Serum creatinine increased significantly in the felodipine group from 128 +/- 61 to 139 +/- 67 mumol/l (p < 0.05) but not in the placebo group (122 +/- 54 to 125 +/- 51 mumol/l (ns)). The values of serum creatinine returned to baseline levels 7 days after angiography. During hydration there was only a slight reduction of GFR after angiography with iohexol. Thus, felodipine had no major effect on GFR after iohexol but, as baseline GFR tended to be lower in the felodipine pre-treated patients, it might have had some renoprotective effect in patients with more advanced renal failure.
authors.affiliation: Department of Nephrology, Linköping University Hospital, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Spångberg-Viklund
authors.forename: J
authors.initials: J
authors.lastname: Berglund
authors.forename: T
authors.initials: T
authors.lastname: Nikonoff
authors.forename: P
authors.initials: P
authors.lastname: Nyberg
authors.forename: T
authors.initials: T
authors.lastname: Skau
authors.forename: R
authors.initials: R
authors.lastname: Larsson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D048909:Diabetes Complications; D003928:Diabetic Nephropathies / Q000150:complications; D015736:Felodipine / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007472:Iohexol / Q000009:adverse effects*; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged
chemical_list: D002121:Calcium Channel Blockers; D003287:Contrast Media; D007472:Iohexol; D003404:Creatinine; D015736:Felodipine